- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Group 1: Peripherally Located Tumors, Group 2: Peripherally Located Chest Wall Adjacent Tumors, Group 3: Centrally Located Tumors
- Radiation
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 2
- States / cities
- Hines, Illinois • Maywood, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,098
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- capmatinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- La Jolla, California • Sacramento, California • Fairfax, Virginia
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
- Interventions
- filgrastim, docetaxel, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Lung Cancer
- Interventions
- cisplatin, vinorelbine ditartrate
- Drug
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2009
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 87 more
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
- Interventions
- VLS-1488
- Drug
- Lead sponsor
- Volastra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- 3-dimensional conformal radiation therapy, bortezomib, paclitaxel, carboplatin
- Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 143
- States / cities
- Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 82 more
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Interventions
- Proton Radiation Therapy, Taxol, Carboplatin
- Radiation · Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2011
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma, Lung Neoplasms
- Interventions
- Drug: Hyperacute Lung Cancer Cell Vaccine
- Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Carcinoma, Non-small Cell Lung
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Tampa, Florida • New York, New York
- Conditions
- Lung Cancer
- Interventions
- gemcitabine hydrochloride, vinorelbine ditartrate, cytogenetic analysis, loss of heterozygosity analysis, microarray analysis, conventional surgery, neoadjuvant therapy
- Drug · Genetic · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- CHR-2797 (tosedostat), erlotinib
- Drug
- Lead sponsor
- Chroma Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Orange, California • Paducah, Kentucky + 4 more
- Conditions
- Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
- Interventions
- MLN8237 and Erlotinib
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lung Cancer, Metastatic Cancer
- Interventions
- 3'-deoxy-3'-[18F]FLT, Single photon emission computed tomography
- Other · Procedure
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
- Interventions
- DSP107, Atezolizumab
- Biological
- Lead sponsor
- Kahr Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 7
- States / cities
- La Jolla, California • Aurora, Colorado • Lake Mary, Florida + 4 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- pictilisib, Placebo, bevacizumab, carboplatin, paclitaxel
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • Encinitas, California + 37 more
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
- Other · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more
- Conditions
- Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
- Interventions
- Cabozantinib, Atezolizumab
- Drug
- Lead sponsor
- Jun Zhang, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell, Non Small Cell Lung Cancer Metastatic
- Interventions
- Nivolumab, Ipilimumab, Nintedanib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Pathologic Stage 0 Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Best Practice, Biospecimen Collection, Endoscopic Procedure, Fecal Microbiota Transplantation, Infliximab, Laboratory Biomarker Analysis, Prednisone, Vedolizumab
- Other · Procedure · Biological + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Carboplatin, Cetuximab
- Drug · Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 8
- States / cities
- Bentonville, Arkansas • Tucker, Georgia • Evanston, Illinois + 5 more
- Conditions
- Recurrent Non-small Cell Lung Cancer
- Interventions
- triapine, gemcitabine hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Durvalumab + SoC chemotherapy, Placebo + SoC chemotherapy
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Long Beach, California • Santa Rosa, California + 12 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- vorinostat, paclitaxel, carboplatin, placebo, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Lung Cancer
- Interventions
- Pemetrexed, Gemcitabine
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee